Q-omics provides the consensus-scored NGFR profile across patient tissues and cancer cell-line models. NGFR expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NGFR is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, NGFR RNA expression shows 16,050 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, and TGCT as cancer lineages where NGFR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NGFR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NGFR survival associations across molecular data types. NGFR RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NGFR RNA expression–survival associations across cancer types. High NGFR expression shows unfavorable associations in BLCA, KIRP, OV and LGG, but favorable associations in KIRC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NGFR RNA expression.
This table summarizes NGFR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NGFR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NGFR shows lower tumor expression in BLCA, COAD, LIHC, BRCA and UCEC and higher tumor expression in KIRC. The BLCA box plot shows higher NGFR RNA expression in normal versus tumor tissue (log2 FC = −2.589, t-test p < 0.001).
This table shows molecular features associated with NGFR in patient tissues and cancer cell lines. In patient samples, NGFR shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NGFR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
